Luc P Brion

Dr. Luc P Brion

Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Georgia, USA
orcid
Professor Emeritus, University of Texas Southwestern Medical...

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2008 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
CMColin J. Morley
Colin J. Morley
PDPeter G. Davis
Peter G. Davis
LDLex W. Doyle
Lex W. Doyle
Luc P BrionLuc P Brion
Luc P Brion
JHJean-Michel Hascoet
Jean-Michel Hascoet
JCJohn B. Carlin
John B. Carlin
Bronchopulmonary dysplasia is associated with ventilation and oxygen treatment. This randomized trial investigated whether nasal continuous positive airway pressure (CPAP), rather than intubation and ventilation, shortly after birth would reduce the rate of death or bronchopulmonary dysplasia in very preterm infants.

20 October 2003 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
Luc P BrionLuc P Brion
Luc P Brion
EBE F Bell
E F Bell
TRT S Raghuveer
T S Raghuveer

1 October 1986 in The Journal of Pediatrics
Verified
Journal Article
Closed access
Luc P BrionLuc P Brion
Luc P Brion
AFAlan R. Fleischman
Alan R. Fleischman
CMCecelia McCarton
Cecelia McCarton
GSGeorge J. Schwartz
George J. Schwartz

1 October 2017 in The Journal of Pediatrics
Verified
Journal Article
Closed access
SCSanjay Chawla
Sanjay Chawla
GNGirija Natarajan
Girija Natarajan
SSSeetha Shankaran
Seetha Shankaran
BCBenjamin Carper
Benjamin Carper
Luc P BrionLuc P Brion
Luc P Brion
JTJanet Taft
Janet Taft

1 April 2006 in Pediatrics
Verified
Journal Article
Closed access
SUSmart Uko
Smart Uko
LSLamia Soghier
Lamia Soghier
MVMelissa Vega
Melissa Vega
JMJeremy Marsh
Jeremy Marsh
GRGerald T. Reinersman
Gerald T. Reinersman
Luc P BrionLuc P Brion
Luc P Brion
OBJECTIVES. To assess whether targeted short-term fluconazole prophylaxis reduces late-onset (>3 days of age) invasive fungal infection (IFI) among very low birth weight infants and extremely low birth weight (ELBW) infants and to assess mortality rates, toxicity, and costs associated with this intervention. METHODS. An observational study of 2 subsequent epochs of inborn infants with birth weight of <1500 g or gestational age of 3 days. RESULTS. IFI was observed for 13 (6.3%) of 206 infants in the control epoch and 2 (1.1%) of 178 in the fluconazole epoch, with a common odds ratio of 0.166. Logistic regression analysis taking into account all published factors (except for fungal colonization) showed that the fluconazole epoch was associated significantly with lower IFI rates. We observed no change in late (>3 days) mortality rates (11 of 206 infants in the control epoch vs 8 of 178 infants in the prophylaxis epoch). The mortality rate for ELBW infants with IFI was low (15%) in our study. Fluconazole was administered to 81% of ELBW infants, who received a median of 8 doses, and 41% of larger infants, who received a median of 5 doses. The intervention was cost-effective, and the effective number needed to treat to prevent 1 IFI was 10. CONCLUSIONS. This study suggests that targeted short-course fluconazole prophylaxis in very low birth weight and ELBW infants may be efficacious and cost effective.

3 October 2020 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
Luc P BrionLuc P Brion
Luc P Brion
RHRoy Heyne
Roy Heyne
CLCheryl S. Lair
Cheryl S. Lair